| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (NCT05367440) | AstraZeneca | 2022-06-02 |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer (NCT05413421) | ORIC Pharmaceuticals | 2022-06-01 |
| MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer (NCT05127850) | University of California, San Francisco | 2022-03-22 |
| 68Ga-PSMA PET/CT for Ra223 Assessment (NCT04951817) | Chang Gung Memorial Hospital | 2022-03-02 |
| The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation (NCT05167175) | Hongqian Guo | 2022-03-01 |
| Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (NCT04925648) | St Vincent's Hospital, Sydney | 2021-10-18 |
| High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (NCT05011383) | VA Office of Research and Development | 2021-08-31 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (NCT04335682) | Alliance Foundation Trials, LLC. | 2021-08-17 |
| 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (NCT04726033) | Telix Pharmaceuticals (Innovations) Pty Limited | 2021-08-04 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (NCT04787744) | VA Office of Research and Development | 2021-07-01 |
| Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC (NCT04846478) | Dana-Farber Cancer Institute | 2021-06-28 |
| The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer (NCT04926155) | Sun Yat-sen University | 2021-06-23 |
| The Effect of Metformin in Patients With Newly Diagnosed mHSPC (NCT04925063) | Sun Yat-sen University | 2021-06-16 |
| A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (NCT04709276) | Andrew J. Armstrong, MD | 2021-06-07 |
| ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (NCT04662580) | Janssen Research & Development, LLC | 2021-05-03 |
| [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer (NCT04528199) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-02-01 |
| Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers (NCT04330716) | Dana-Farber Cancer Institute | 2020-12-01 |
| Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) (NCT04070209) | Sir Mortimer B. Davis - Jewish General Hospital | 2020-10-19 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (NCT04446117) | Exelixis | 2020-10-19 |
| Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy (NCT04533958) | Saint-Gregoire Private Hospital Center | 2020-09-28 |
| mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer (NCT04545697) | University of California, San Francisco | 2020-09-18 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| PROState Pathway Embedded Comparative Trial (NCT04400656) | Imperial College London | 2020-09-08 |
| Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (NCT04332744) | MedSIR | 2020-09-02 |
| PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study (NCT04086966) | University of Alabama at Birmingham | 2020-08-20 |
| Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (NCT04085991) | Sir Mortimer B. Davis - Jewish General Hospital | 2020-07-31 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer (NCT04262154) | Memorial Sloan Kettering Cancer Center | 2020-03-03 |
| imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS (NCT04746300) | Radboud University Medical Center | 2020-02-04 |
| PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer (NCT04220983) | Weill Medical College of Cornell University | 2020-01-27 |
| Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer (NCT05471427) | Azienda Ospedaliero-Universitaria Careggi | 2020-01-01 |
| Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO (NCT03934164) | Institute of Cancer Research, United Kingdom | 2019-11-28 |
| A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (NCT04179864) | Epizyme, Inc. | 2019-11-18 |
| Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC (NCT04193657) | University Health Network, Toronto | 2019-10-25 |
| Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer (NCT04067713) | University College, London | 2019-09-20 |
| Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer (NCT04031378) | Fundacao Champalimaud | 2019-09-01 |
| Impact of Atorvastatin on Prostate Cancer Progression During ADT (NCT04026230) | Tampere University Hospital | 2019-08-15 |
| Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer (NCT04030338) | Memorial Sloan Kettering Cancer Center | 2019-07-19 |
| The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (NCT03977610) | Chang Gung Memorial Hospital | 2019-06-01 |
| I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). (NCT03939689) | Progenics Pharmaceuticals, Inc. | 2019-05-30 |
| PRostate Cancer Plasma Integrative Multi-modal Evaluation (NCT06981377) | Santa Chiara Hospital | 2019-05-07 |
| A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer (NCT03871816) | Janssen Research & Development, LLC | 2019-04-22 |
| Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (NCT03763253) | Imperial College London | 2019-04-10 |
| Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (NCT03764540) | Centre hospitalier de l'Université de Montréal (CHUM) | 2019-04-01 |
| Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers (NCT03585114) | Columbia University | 2018-12-11 |
| Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia (NCT03867357) | Seattle Institute for Biomedical and Clinical Research | 2018-12-07 |
| COMbination of Bipolar Androgen Therapy and Nivolumab (NCT03554317) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-05 |
| Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases (NCT03143322) | UNICANCER | 2018-07-24 |
| Cannabis Oil and Radiation Therapy for the Management of Pain (NCT03763851) | Tetra Bio-Pharma | 2018-03-14 |
| Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC (NCT03432949) | University Health Network, Toronto | 2018-02-23 |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects (NCT03248570) | University of California, San Francisco | 2018-02-20 |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer (NCT03181867) | National Cancer Institute (NCI) | 2017-08-03 |
| Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (NCT03072238) | Hoffmann-La Roche | 2017-06-30 |
| 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer (NCT03173924) | National Cancer Institute (NCI) | 2017-06-06 |
| Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers (NCT03073473) | Cota Inc. | 2017-02-28 |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) (NCT03050866) | Erasmus Medical Center | 2017-02-21 |
| Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors (NCT02744287) | Regeneron Pharmaceuticals | 2016-11-30 |
| One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ (NCT02962284) | Sun Pharmaceutical Industries Limited | 2016-11-01 |
| Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration (NCT02963155) | Institut Paoli-Calmettes | 2016-11-01 |
| Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer. (NCT03497377) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-05-16 |
| Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients (NCT02655952) | WntResearch AB | 2016-04-01 |
| Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) (NCT02500901) | Paul Mathew, MD | 2016-03-01 |
| Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients (NCT06350825) | The First Affiliated Hospital with Nanjing Medical University | 2016-01-01 |
| INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4) (NCT02730338) | Movember Foundation | 2016-01-01 |
| Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (NCT02380274) | Astellas Pharma Global Development, Inc. | 2015-03-27 |
| Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer (NCT02278055) | Memorial Sloan Kettering Cancer Center | 2014-10-08 |
| Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer (NCT02260817) | Global Isotopes, LLC d/b/a Zevacor Molecular | 2014-10-01 |
| A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease (NCT01933022) | Astellas Pharma Europe Ltd. | 2014-08-01 |
| Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer (NCT02206724) | Sharp HealthCare | 2014-07-16 |
| Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (NCT02051218) | Swiss Cancer Institute | 2014-07-16 |
| Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer (NCT02151760) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2014-05-01 |
| Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. (NCT02036060) | Spanish Oncology Genito-Urinary Group | 2014-02-07 |
| Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer (NCT02049190) | Arno Therapeutics | 2014-02-01 |
| A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (NCT02066961) | Astellas Pharma Global Development, Inc. | 2013-12-31 |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer (NCT01957436) | UNICANCER | 2013-11-13 |
| A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer (NCT01981122) | Dendreon | 2013-09-01 |
| Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer (NCT01923727) | ImaginAb, Inc. | 2013-08-01 |
| Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients (NCT01677897) | Kantonsspital Graubünden | 2013-08-01 |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel (NCT01814150) | Gottfried Maya | 2013-04-01 |
| Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer (NCT01815515) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-03-01 |
| Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer (NCT01560923) | Masonic Cancer Center, University of Minnesota | 2012-10-01 |
| Second-line Chemotherapy in Castration Resistant Prostate Cancer (NCT01558219) | Tampere University Hospital | 2011-11-01 |
| Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer (NCT01303705) | Providence Health & Services | 2010-10-14 |
| Biomarkers of Bone Resorption in Metastatic Prostate Cancer (NCT01233557) | University of Aberdeen | 2010-09-01 |
| Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC (NCT01062503) | University Health Network, Toronto | 2010-01-01 |
| Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer (NCT01012141) | Centre Jean Perrin | 2009-09-01 |
| A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (NCT00942578) | National Cancer Institute (NCI) | 2009-07-16 |
| Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines (NCT01153113) | University of Florida | 2008-01-01 |
| Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer (NCT00439270) | Bristol-Myers Squibb | 2007-07-01 |
| Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) (NCT00452387) | Accelerated Community Oncology Research Network | 2007-05-01 |
| Phase II Sunitinib Prog Met AIPC (NCT00599313) | US Oncology Research | 2007-03-01 |
| Collection of Blood From Patients With Prostate Cancer (NCT00923221) | National Cancer Institute (NCI) | 2007-02-28 |
| Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer (NCT00441571) | Cytogen Corporation | 2007-02-01 |
| ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer (NCT00415779) | National Cancer Institute, Naples | 2006-07-01 |
| Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer (NCT00494338) | Sanofi | 2004-11-01 |
| CMAB vs IMAB in Metastatic Prostate Cancer (NCT00255268) | AstraZeneca | 2004-08-01 |
| Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer (NCT00541281) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2003-12-01 |
| PROSTACOX : Metastatic Prostate Chemotherapy (NCT00213694) | University Hospital, Rouen | 2003-11-01 |
| Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy (NCT00216060) | Christopher Sweeney, MBBS | 2003-10-01 |
| Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer (NCT00003533) | Burzynski Research Institute | 1996-02-27 |